Every Biosimilar Should Have Its Own Medicare Pay Code, CMS Told
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz and other biosimilar stakeholders react at a public meeting to indications that CMS might be planning to put multiple biosimilars into a single Medicare billing code, meaning they would all be reimbursed at the same amount, when they reference the same innovator product.